Home » Stocks » PTN

Palatin Technologies, Inc. (PTN)

Stock Price: $1.15 USD 0.14 (13.86%)
Updated Jan 21, 2021 4:00 PM EST - Market closed
Market Cap 232.20M
Revenue (ttm) -267,950
Net Income (ttm) -21.87M
Shares Out 236.35M
EPS (ttm) -0.10
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 21
Last Price $1.15
Previous Close $1.01
Change ($) 0.14
Change (%) 13.86%
Day's Open 1.18
Day's Range 1.10 - 1.25
Day's Volume 22,706,591
52-Week Range 0.36 - 1.25

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 1 month ago

CRANBURY, N.J., Dec. 15, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules th...

Zacks Investment Research - 2 months ago

Palatin Technologies (PTN) saw a big move last session, as its shares jumped 8% on the day, amid huge volumes.

Seeking Alpha - 2 months ago

Palatin Technologies, Inc. (PTN) CEO Carl Spana on Q1 2021 Results - Earnings Call Transcript

PRNewsWire - 2 months ago

CRANBURY, N.J., Nov. 17, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules th...

PRNewsWire - 2 months ago

CRANBURY, N.J., Nov. 12, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter, fiscal year 2021 operating results on Tuesday, November 17, 2020 ...

Seeking Alpha - 3 months ago

Palatin Technologies, Inc. (PTN) CEO Carl Spana on Q4 2020 Results - Earnings Call Transcript

PRNewsWire - 3 months ago

CRANBURY, N.J., Sept. 28, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules t...

PRNewsWire - 3 months ago

CRANBURY, N.J., Sept. 24, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2020 operating results on Monday, September ...

PRNewsWire - 4 months ago

CRANBURY, N.J., Sept. 10, 2020 /PRNewswire/ -- Palatin Technologies, Inc.

PRNewsWire - 5 months ago

CRANBURY, N.J., Aug. 13, 2020 /PRNewswire/ -- Palatin Technologies, Inc.

PRNewsWire - 5 months ago

CRANBURY, N.J., Aug. 5, 2020 /PRNewswire/ -- Palatin Technologies, Inc.

Market Watch - 6 months ago

Shares of Palatin Technologies Inc. PTN, +2.50% gained 31.8% in premarket trading on Tuesday after it said it would test one of its investigational drugs as a treatment for COVID-19.

Seeking Alpha - 8 months ago

Palatin Technologies, Inc. (PTN) CEO Carl Spana on Q3 2020 Results - Earnings Call Transcript

Seeking Alpha - 11 months ago

Palatin Technologies, Inc. (PTN) CEO Carl Spana on Q2 2020 - Earnings Call Transcript

Seeking Alpha - 1 year ago

Palatin Technologies' (PTN) CEO Carl Spana on Q1 2020 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Every 10% of market share captured by Vyleesi is likely to generate $27 million in royalties for PTN.

Seeking Alpha - 1 year ago

Palatin Technologies, Inc. (NYSEMKT:PTN) Q4 2019 Earnings Conference Call September 12, 2019 11:00 AM ET

Zacks Investment Research - 1 year ago

Investors will focus on pipeline updates, when Palatin (PTN) releases fourth-quarter fiscal 2019 results.

Zacks Investment Research - 1 year ago

In the latest trading session, Palatin (PTN) closed at $0.91, marking a -1.7% move from the previous day.

Zacks Investment Research - 1 year ago

Is (PTN) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 1 year ago

Palatin (PTN) closed the most recent trading day at $1, moving +0.37% from the previous trading session.

The Motley Fool - 1 year ago

A high-profile analyst questioned the company's recent FDA approval.

Market Watch - 1 year ago

Shares of Palatin Technologies Inc. rocketed 27% in very active premarket trading Monday, after a positive Food and Drug Administration decision on AMAG Pharmaceuticals Inc. treatment for hypo...

Seeking Alpha - 1 year ago

The demanded phase I trial showed consistent results compared to the previous trials and AMAGs CEO is: "fairly optimistic about the approval ability" of Vyleesi.

The Motley Fool - 1 year ago

Two hope to pick up additional indications for existing blockbuster drugs, while another could score a big victory for a new drug.

Other stocks mentioned: ALXN, AMAG, MRK
Seeking Alpha - 1 year ago

Palatin Technologies' (PTN) CEO Carl Spana on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Palatin Technologies (PTN) shares rose nearly 6% in the last trading session, amid huge volumes.

Other stocks mentioned: ANIP

About PTN

Palatin Technologies, a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is also developing oral PL8177, a selective melanocortin receptor (MCr) 1 agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and systemic PL8177... [Read more...]

Industry
Biotechnology
IPO Date
Oct 28, 1993
CEO
Carl Spana
Employees
20
Stock Exchange
NYSEAMERICAN
Ticker Symbol
PTN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for PTN stock is "Strong Buy." The 12-month stock price forecast is 2.33, which is an increase of 102.61% from the latest price.

Price Target
$2.33
(102.61% upside)
Analyst Consensus: Strong Buy